Celltech Codeprex Approved For 12-Hour Cough Suppression
This article was originally published in The Pink Sheet Daily
Executive Summary
Celltech expects the codeine-based antitussive to hit retail pharmacy shelves by the fourth quarter. The extended-release formulation eliminates the need for middle of the night dosing, the company says.
You may also be interested in...
Celltech Finds CDP-870 Partner In UCB; BLA Filing Expected By 2007
The licensing agreement gives Celltech a means through which to commercialize the TNF inhibitor should the companies' proposed $2.7 bil. merger agreement fall through. UCB/Celltech will be fifth largest biotech company worldwide.
Bristol To Name New R&D Head Shortly
Senior VP-Global Clinical & Pharmaceutical Development Elliott Sigal is acting president of Bristol-Myers Squibb’s research institute following the death of James Palmer.
Aranesp Performance Strong Heading Into "Transition" Time, Amgen Says
The company is talking with oncologists about Aranesp ahead of a switch in Medicare reimbursement in January 2005. U.S. sales for the red blood cell product were up 32% in the third quarter.